# US 2003/0229907 A1 · Transgenic non-human mammals with progressive neurologic disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229907 A1
- Document ID: US20030229907A1
- Status: Published application
- Kind: A1
- Application number: 10/271,314
- Filed: 2002-10-15
- Published: 2003-12-11
- Earliest claimed: 1994-01-27
- Assignees: The John Hopkins University, a Maryland corporation; Regents of the University of Minnesota, a Minnesota corporation
- Inventors: Karen Hsiao; David R. Borchelt; Sangram S. Sisodia
- Web page: https://patentgrep.com/patent/US20030229907A1

## CPC

- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A01K 67/0278: Knock-in vertebrates, e.g. humanised vertebrates
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 14/4711: {Alzheimer's disease; Amyloid plaque core protein}
- A01K 2207/15: Humanized animals
- A01K 2217/00: Genetically modified animals
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2227/105: Murine
- A01K 2267/0312: Animal model for Alzheimer's disease
- A01K 2267/0318: Animal model for neurodegenerative disease, e.g. non- Alzheimer's
- A01K 2267/0343: Animal model for prion disease
- A01K 2267/0356: Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided is a transgenic non-human eukaryotic animal whose germ cells and somatic cells contain the amyloid precursor protein sequence introduced into the animal, or an ancestor of the animal, at an embryonic stage. In mice, an age-related CNS disorder characterized by agitation, neophobia, seizures, inactivity, diminished cerebral glucose utilization, cortico-limbic gliosis, and death, develops. An acceleration of this disorder occurs in transgenic mice expressing human and mouse Alzheimer amyloid precursor proteins (APP) produced using a hamster prion protein gene-derived cosmid vector that confers position-independent, copy number-dependent expression. In transgenic mice the disorder develops in direct relationship to brain levels of transgenic APP, but mutant APP confers the phenotype at lower levels of expression than wild-type APP. The disorder occurs in the absence of extracellular amyloid deposition, indicating that some pathogenic activities of APP are dissociated from amyloid formation.

## Claims

### Claim 1

A transgenic non-human mammal, said mammal comprising:
an amount of amyloid precursor protein expression in neurologic tissues of said mammal sufficient to produce impaired performance of said mammal in memory and learning tests and to induce abnormal neuropathology in a cortico-limbic region of said mammal's brain, wherein said impaired performance and said abnormal neuropathology are as compared to control mammals.

### Claim 2 (depends on 1)

The transgenic non-human mammal according to claim 1, wherein said amyloid precursor protein expression is at least about two-fold that of endogenous amyloid precursor protein in a control mammal.

### Claim 3 (depends on 1)

The transgenic non-human mammal according to claim 1, wherein said abnormal neuropathology is thioflavin S positive amyloid plaques.

### Claim 4 (depends on 1)

The transgenic non-human mammal according to claim 1, wherein said amyloid precursor protein is encoded by a coding sequence derived from a mutant amyloid precursor protein gene.

### Claim 5 (depends on 4)

The transgenic non-human mammal according to claim 4, wherein said mutant amyloid precursor protein gene is other than a codon 717 mutant.

### Claim 6 (depends on 4)

The transgenic non-human mammal according to claim 4, wherein said coding sequence is substantially free of splice sites.

### Claim 7 (depends on 4)

The transgenic non-human mammal according to claim 4, wherein said coding sequence is substantially free of a Kunitz-protease inhibitor domain.

### Claim 8 (depends on 1)

The transgenic non-human mammal according to claim 1, wherein said mammal is a rodent.

### Claim 9 (depends on 8)

The transgenic non-human mammal according to claim 8, wherein said rodent is a mouse.

### Claim 10 (depends on 9)

The transgenic non-human mammal according to claim 9, wherein a nontransgenic ancestor of said mouse is from a strain having greater longevity as compared with other strains of mice.

### Claim 11 (depends on 1)

The transgenic non-human mammal according to claim 1, wherein said expression is obtained using regulatory sequences derived from a prion protein gene operatively linked to a coding sequence encoding said amyloid precursor protein.

### Claim 12 (depends on 1)

Progeny of said transgenic non-human mammal according to claim 1.

### Claim 13

A method for screening for an agent which ameliorates symptoms of Alzheimer's disease, said method comprising:
comparing performance on memory and learning tests of a first transgenic non-human mammal contacted with said agent and a second transgenic non-human mammal not contacted with said agent, wherein said first and said second non-human transgenic mammals express amyloid precursor protein in neurologic tissues in an amount sufficient to impair performance on said memory and learning tests as compared to control mammals, whereby an agent which ameliorates said symptoms is identified by superior performance of said first transgenic non-human mammal as compared to said second transgenic non-human mammal on said memory and learning tests.

### Claim 14

A method for screening for an agent useful for treating Alzheimer's disease, said method comprising:
comparing performance on memory and learning tests of a first transgenic non-human mammal contacted with said agent and a second transgenic non-human mammal not contacted with said agent, wherein said first and said second non-human transgenic mammals express amyloid precursor protein in neurologic tissues in an amount sufficient to impair performance on said memory and learning tests as compared to control mammals; and
comparing neuropathology in a cortico-limbic region of the brain of said first and said second transgenic non-human mammals when said first transgenic non-human mammal exhibits superior performance on said memory and learning tests as compared to said second transgenic non-human mammal, whereby an agent which is useful for treating Alzheimer's disease is identified by a decrease in neuropathologic findings in said first transgenic non-human mammal as compared to said second transgenic non-human mammal.

### Claim 15 (depends on 14)

The method according to claim 14, wherein said decreased neuropathologic findings are one or more findings selected from the group consisting of:
a reduction in number of thioflavin S-positive Aβ deposits;
a reduction in amount of thioflavin S-positive Aβ deposits a reduction of hypertrophic gliosis in cortico-limbic structures of said brain;
a reduction of diminution of 2-deoxyglucose uptake in cortico-limbic structures of said brain;
a reduction of diminution of 2-deoxyglucose utilization in cortico-limbic structures of said brain.

### Claim 16

A method for screening for an agent useful for treating Alzheimer's disease, said method comprising:
comparing performance on memory and learning tests of a first transgenic non-human mammal contacted with said agent and a second transgenic non-human mammal not contacted with said agent, wherein said first and said second non-human transgenic mammals express amyloid precursor protein in neurologic tissues in an amount sufficient to impair performance on said memory and learning tests as compared to control mammals; and
comparing age of death of said first and said second transgenic non-human mammals when said first transgenic non-human mammal exhibits superior performance on said memory and learning tests as compared to said second transgenic non-human mammal, whereby an agent which is useful for treating Alzheimer's disease is identified by a greater age at death of said first transgenic non-human mammal as compared to said second transgenic non-human mammal.

### Claim 17

A method for screening for an agent which ameliorates symptoms of Alzheimer's disease, said method comprising:
comparing exploratory behavior or locomotor behavior of a first transgenic mouse contacted with said agent and a second transgenic mouse not contacted with said agent, wherein said first and said second transgenic mice express amyloid precursor protein in neurologic tissues in an amount sufficient to produce impaired performance on said exploratory and locomotor behavior as compared to control mice, whereby an agent which ameliorates said symptoms is identified by less impaired exploratory or locomotor behavior in said first transgenic mouse as compared to said second transgenic mouse.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said exploratory or locomotor behavior is assessed using a corner index test.

### Claim 19 (depends on 17)

The method according to claim 17, wherein a nontransgenic ancestor of said mouse is from a strain selected from the group consisting of FVB, Swiss Webster, and C57B6.

### Claim 20 (depends on 17)

The method according to claim 17, wherein said amyloid precursor protein is encoded by a coding sequence derived from a K670N-M671L amyloid precursor protein gene.
